

EDITORIAL

ASTHMA AND MAST CELL BIOLOGY

S.K. KRITAS¹, A. SAGGINI², G. CERULLI³, A. SPEZIALI³, A. CARAFFA⁴, P. ANTINOLFI⁴,
A. PANTALONE⁵, M. ROSATI⁶, M. TEF³, R. SAGGINI⁷ and P. CONTI⁸

¹Department of Microbiology and Infectious Diseases, School of Veterinary Medicine, Aristotle University of Thessaloniki, Macedonia, Greece; ²Department of Dermatology, University of Rome Tor Vergata, Rome, Italy; ³Nicola's Foundation, Onlus, Arezzo, Italy; ⁴Orthopedic Division, University of Perugia, Perugia, Italy; ⁵Orthopedic Division, University of Chieti-Pescara, Chieti, Italy; ⁶Gynecology Clinic, Pescara Hospital, Pescara, Italy; ⁷Department of Neurosciences and Imaging, Faculty of Medicine and Surgery, G. d'Annunzio University Chieti-Pescara, Chieti, Italy; ⁸Immunology Division, Medical School, University of Chieti-Pescara, Chieti, Italy

Received May 30, 2014 – Accepted July 10, 2014

Asthma is a chronic inflammatory disease of the lung and its pathophysiology is initiated by mast cell activation in response to the antigen binding to IgE receptor as well as by TH2 cell activation. Mast cells are well established effector cells in asthma where they exacerbate the inflammatory response, playing a key role in early phase, degranulating and increasing histamine. Human mast cells possess high affinity IgE receptors and are ubiquitous but predominantly localized in mucosal and connective tissue and are distributed along blood vessels. There are two types of mast cells: connective tissue mast cells (TC) and mucosal mast cells (T mast cells). TC mast cells contain more heparin, whereas T mast cells contain more chondroitin sulfate. In asthma, mast cell activation can trigger degranulation, releasing secretory granule complex and preformed mediators, such as histamine and proteases, along with the synthesis of leukotrienes and prostaglandins, and induction of cytokines and chemokines. Leukotriene inhibitors and omalizumab, which inhibits IgE, both relieve the asthma exacerbation when administered to humans and permit to reduce the use of other drugs. The release of cytokines by mast cells, such as TNF- α , IL-1, IL-6 and IL-33, participate in the pathogenesis of asthma. Stress worsens asthma, and this effect is also mediated by mast cell activation through the release of cytokines. Administration of IL-33 in experimental animals provokes pathological effects in the mucosal tissues and augments antibody IgE and IgA in blood vessels. Here, we report the impact of mast cell biology in asthma pathogenesis.

1721-727X (2014)

Copyright © by BIOLIFE, s.a.s.

This publication and/or article is for individual use only and may not be further reproduced without written permission from the copyright holder.

Unauthorized reproduction may result in financial and other penalties

DISCLOSURE: ALL AUTHORS REPORT NO CONFLICTS OF INTEREST RELEVANT TO THIS ARTICLE.